Piclidenoson
Sponsors
Can-Fite Biopharma Ltd., Can-Fite BioPharma
Conditions
COVID-19Coronavirus InfectionLowe SyndromePlaque PsoriasisPlaque psoriasis
Phase 2
Piclidenoson for Treatment of COVID-19
CompletedNCT04333472
Start: 2021-01-06End: 2022-04-21Updated: 2022-04-22
An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome
Not yet recruitingNCT07410455
Start: 2026-06-01End: 2027-08-31Target: 5Updated: 2026-02-18
Phase 3
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
Not yet recruitingNCT06643260
Start: 2025-06-30End: 2028-06-30Target: 705Updated: 2025-04-29
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Subjects with Moderate-to-Severe Plaque Psoriasis
RecruitingCTIS2024-519919-34-00
Start: 2025-08-18Target: 248Updated: 2026-01-12